See more : eBay Inc. (EBAY) Income Statement Analysis – Financial Results
Complete financial analysis of NRx Pharmaceuticals, Inc. (NRXP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NRx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aspen Technology, Inc. (AZPN) Income Statement Analysis – Financial Results
- Fineqia International Inc. (FNQQF) Income Statement Analysis – Financial Results
- Greencore Group plc (GNCGY) Income Statement Analysis – Financial Results
- Casa de Bolsa Finamex S.A.B. de C.V. (FINAMEXO.MX) Income Statement Analysis – Financial Results
- Rimon Consulting & Management Services Ltd. (RMON.TA) Income Statement Analysis – Financial Results
NRx Pharmaceuticals, Inc. (NRXP)
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 4.00K | 2.00K | 907.41K | 0.00 | 1.01M | 0.00 |
| Gross Profit | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | -1.01M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.50K | 0.00 | 0.00 |
| General & Administrative | 14.22M | 27.37M | 74.94M | 11.44M | 2.77K | 0.00 | 0.00 |
| Selling & Marketing | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | 0.00 |
| Other Expenses | 0.00 | -505.00K | -771.00K | -10.16M | 713.19K | 1.01M | 0.00 |
| Operating Expenses | 27.58M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Cost & Expenses | 27.59M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Interest Income | 494.00K | 249.00K | 18.00 | 56.00 | 1.21M | 1.09M | 0.00 |
| Interest Expense | 120.00K | 0.00 | 18.00K | 56.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | 1.09M | 52.52K |
| EBITDA | -30.03M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -27.59M | -44.40M | -115.80M | -51.39M | -6.26K | -1.01M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | 4.58M | 22.73M | -39.88M | 1.21M | 1.09M | -105.03K |
| Income Before Tax | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.00K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | 0.00 |
| Net Income | -30.15M | -35.24M | -71.72M | -12.35M | 408.43K | 66.10K | -105.03K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EPS Diluted | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| Weighted Avg Shares Out | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
| Weighted Avg Shares Out (Dil) | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors
Former Inspector General, US Dept. of Health and Human Services Former Assistant US Attorney for the Eastern District of Virginia Nationally recognized attorney in highly regulated industries; healthcare specialist RADNOR, Pa.
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and...
3 Penny Stocks Under $3 To Watch Right Now
As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk.
NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment
New York, December 19, 2023 – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company's shares surged 25% in trading on Monday following...
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression
Ketamine, an NMDA blocker, was highly effective compared to active comparator in rapidly reducing Suicidality (p=0.0003) This study represents the second well-controlled trial NRx has licensed supporting the use of IV Ketamine in suicidal depression NRx plans to present the...
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
"Study May Proceed" letter received from FDA Potential to initiate registrational study in 2024 RADNOR, Pa. , Dec. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that its Investigational New...
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders
RADNOR, Pa. , Dec. 13, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced their 2023 Annual Meeting of Stockholders (the "Annual Meeting") to be held on December 19, 2023, at 11:00 a.m.
NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event
RADNOR, Pa. , Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from...
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
RADNOR, Pa. , Nov. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Founder and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at...
Source: https://incomestatements.info
Category: Stock Reports